PGEN Stock — Precigen Inc.: Cash, EV, Pipeline

Share price

$7.78

Market cap

$2,785.5M

Cash

$38.2M

Enterprise value

$2,841.2M

Balance sheet

Cash	$38.2M
Debt	$93.9M
Net cash	-$55.7M
Enterprise value	$2,841.2M
Basic shares	358.0M shares
Fully diluted shares	438.3M shares
Fully diluted market cap	$3,409.9M
Cash per share	$0.11

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading PGEN daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 23, 2026 - Feb 3, 2027	PRGN-2009 plus Pembrolizumab	Phase 2	Cervical Cancer; HPV-Related Carcinoma; HPV-Related Malignancy	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PRGN-2009

Phase 2 · Active Modality: off-the-shelf adenoviral vector immunotherapy (AdenoVerse)

Target HPV

Partnerships National Cancer Institute: CRADA (Phase 2 development)

Indications

Recurrent/metastatic cervical cancer (Phase 2)
Newly diagnosed HPV-associated oropharyngeal cancer (Phase 2)

Status note In Phase 2 for HPV-associated cancers under NCI CRADA: R/M cervical cancer in combination with pembrolizumab; two newly-diagnosed oropharyngeal cancer trials (with pembrolizumab, and with neoadjuvant chemotherapy).

PRGN-3006

Phase 1 · Active Modality: autologous CAR-T (UltraCAR-T platform)

Target CD33 (Siglec-3)

Indications

Relapsed/refractory AML (Phase 1)
High-risk MDS (Phase 1)

Status note Phase 1b enrollment complete. FDA Fast Track designation and Orphan Drug Designation in AML; company seeking strategic partnership to advance the program.

PRGN-3005

Phase 1 · Active Modality: autologous CAR-T (UltraCAR-T platform)

Target MUC16 (Mucin 16, unshed portion)

Indications

Advanced recurrent platinum-resistant ovarian / fallopian tube / primary peritoneal cancer (Phase 1)

Status note Phase 1 dose escalation completed; enrollment in Phase 1b paused as part of Aug 2024 strategic prioritization.

PRGN-3007

Phase 1 · Active Modality: autologous CAR-T (next-generation UltraCAR-T platform)

Target ROR1

Indications

ROR1+ hematologic malignancies (Phase 1)
ROR1+ solid tumors (TNBC) (Phase 1)

Status note Phase 1 enrollment paused as part of Aug 2024 strategic prioritization.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PRGN-2009 plus Pembrolizumab
Lead indication	Cervical Cancer
Lead phase	Phase 2
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06157151	Phase 2	Recruiting	Sponsor	PGEN	—	Cervical Cancer; HPV-Related Carcinoma; HPV-Related Malignancy	—
NCT04724980	Phase 2	Active, not recruiting	Sponsor	PGEN	—	Recurrent Respiratory Papillomatosis; Papillomavirus Infections; Papillomaviridae	—
NCT03927261	Phase 1	Active, not recruiting	Sponsor	PGEN	—	Acute Myeloid Leukemia; Myelodysplastic Syndromes	—
NCT03907527	Phase 1	Active, not recruiting	Sponsor	PGEN	—	Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma	—
NCT06538480	Not disclosed	Recruiting	Sponsor	PGEN	—	Recurrent Respiratory Papillomatosis; Papillomavirus Infection; Papillomaviridae	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Precigen, Inc on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

PGEN — Precigen Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials